A major shot in the arm is set to boost South Africa’s fight against tuberculosis.
A grant from the Global Fund is expected to boost the implementation of tuberculosis drug 3HP, a short course TB preventative therapy regimen that combines TB drugs, isoniazid and rifapentine. South African National Aids Council CEO, Sandile Buthelezi is excited that the grant will assist with the rolling out of 3HP, which is recommended for people living with HIV.
“We are in the process of registering the drug and have dedicated some of the money from the grant to assist with the rollout. We hope that before the end of this year, 3HP will be registered by the South African Health Products Regulatory Authority.”
According to Buthelezi, 3HP will improve the adherence of patients to taking the drug because it is taken for a shorter period, with one dose a week and has fewer side effects than current treatment. Modelling studies also indicate that 3HP is cost-effective, reducing the economic burden of TB control efforts.